IL22 and metabolic dysfunction-associated steatotic liver disease: In various models of diet-induced MASLD, IL-22 improved glucose tolerance, enhanced insulin sensitivity, and reduced body weight along with decreased adiposity (147, 232–234), via mechanisms dependent on STAT3 and Akt activation (232–234).